Skip to main content
MED logo

MED · Medifast Inc

Track MED — free
$11.44 -0.04 (-0.35%) At close · Aug 14
Market Cap
$127.91M
Shares
11.18M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$11.44 Open$11.44 Day$11.40–11.66 52W close$9.45–14.57 Avg vol 30d189K Short int1.5M · 13.3% float · 9.2d Short vol75% Last earningsAug 3, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 3

Up next

Next earnings call
Nov 2, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Aug 3, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +2%
      above
      Price vs 50-day avg +4%
      above
      RSI (14) 53
      neutral
      MACD trend Positive
      52-week position 39%
      mid-range
      Volume (OBV) Bearish div.
      distributing
      Momentum
      relative strength
      Strong
      1-month return +12%
      trailing
      6-month return +8%
      trailing
      YTD return +7%
      this year
      Relative strength −6%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $11 › 200d $11 — 200d above 50d
      Institutional flow Distributing
      -3% holders QoQ · +24 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      13.28% of float · ▼ -9.5% MoM · 9.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      111 holders — near 3-yr low, contrarian setup
      Squeeze score 79
      high risk · 0–100
      Fundamentals
      Strong
      Revenue growth +31%
      Y/Y
      Gross margin 29%
      contracting
      EPS growth −995%
      Y/Y
      Free cash flow $1.2M
      Buyback $20.0M
      remaining
      Balance sheet $89.3M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 54%
      annualized · 1-yr
      Max drawdown −35%
      past year
      ATR 5.3%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 4 of last 5
      Latest guidance · from the 8-K filed Aug 3, 2026
      third quarter 2026
      Revenue $60M – $80M
      Loss per share $-0.65 – $-0.15
      full year 2026
      Revenue $270M – $300M
      Loss per share $-1.75 – $-0.25
      Prior guidance period ended · from the 8-K filed May 4, 2026
      Revenue · second quarter 2026 $60M – $80M
      Loss per share · second quarter 2026 $-1.00 – $-0.50
      Guided vs delivered · last 5 settled
      Revenue fourth quarter 2025
      guided $65M – $80M
      $75.1M In line
      Revenue second quarter
      guided $150M – $170M
      $168.56M In line
      EPS second quarter
      guided $0.05 – $0.40
      $-0.75 Miss −433.3%
      Revenue first quarter
      guided $155M – $175M
      $174.74M In line

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +2% Bullish
      Price vs 50-day avg
      +4% Bullish
      RSI (14)
      53 Neutral
      MACD trend
      Positive Bullish
      52-week position
      39% Neutral
      Volume (OBV)
      Bearish div. Bearish
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $11 › 200d $11 — 200d above 50d
      Institutional flow Distributing
      -3% holders QoQ · +24 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      13.28% of float · ▼ -9.5% MoM · 9.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      111 holders — near 3-yr low, contrarian setup
      Price context
      position in its 52-week range
      Range low $9 Now $11 · 39% Range high $15
      vs 200-day avg +2% vs 50-day avg +4%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Personal Services — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      MED
      Medifast Inc
      this stock
      $127.91M +7.1% +31.0% 13.3%
      ROL
      Rollins Inc
      $17.42B -39.7% +7.2% 32.9 4.0%
      SCI
      Service Corp International
      $11.51B +8.0% +2.9% 22.0 4.8%
      HRB
      H&R Block Inc
      $6.65B +23.7% -1.3% 14.0%
      FTDR
      Frontdoor, Inc.
      $5.96B +49.9% +13.6% 4.4%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      111
      % held
      82.5%
      Net QoQ
      -1.0M sh
      Top holder
      RENAISSANCE TECHNOLOGIES…
      Held Float
      View
      Held by Funds
      Fund positions
      152
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      1.5M
      Days to cover
      9.2d
      Change
      -155.1K sh
      View
      Short Volume
      Short vol %
      75%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      1.2K
      Value
      $12.4K
      As of
      Jul 10, 2026
      View
      Off-Exchange
      Off-exchange %
      42.4%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Sell
      Member
      Donna Shalala
      Amount
      $1.0K–$15.0K
      Traded
      Jun 24, 2019
      View
      Financials
      Financials
      Revenue (FY)
      $385.8M
      Net income (FY)
      $-18.7M
      EPS diluted
      $-1.70
      View
      Buybacks
      Authorized
      $100.0M
      Remaining
      $20.0M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 3, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $159.9K
      Shares
      4.1K
      Filed
      Mar 8, 2024
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 3, 2026
      View
      Investor Relations
      Latest news
      Medifast Announces Second Quarter…
      Published
      Aug 3, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      MED -9.4% +11.5% +7.9% +16.4% +7.1%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -9.8% +7.1% -5.9% +12.5% -6.7%

      Capital returns

      Latest dividend
      $1.65 / share · ex Sep 18, 2023
      Raised 0.6%
      Paid (TTM)
      $0.00 / share · 0 payouts
      Dividend yield (TTM, derived)
      · no payout in the trailing year
      Buyback program · as of Jun 30, 2022
      Authorized
      $100.00M
      Spent (derived)
      $80.00M
      Remaining
      $20.00M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 910329 CUSIP 58470H101 13F (30d) 109 filings 107 filers Visit website Investor relations